Alefacept for chronic plaque psoriasis: a selective therapy with long-lasting disease remissions and an encouraging safety profile.
Alefacept (Amevive) is a recombinant, fully human fusion protein that selectively targets memory T cells that have been implicated in the pathogenesis of psoriasis. Alefacept is approved in the United States as a treatment for chronic plaque psoriasis. Alefacept is unique among treatments for moderate to severe psoriasis because of its selective therapeutic action, favorable safety profile, and ability to induce lengthy disease remissions.
Leone
Gina
G
Amevive, Biogen, Inc, Cambridge, MA, USA.
Rolston
Kathy
K
Spaulding
Gail
G
D000077944:Alefacept; D002908:Chronic Disease; D003142:Communication; D006801:Humans; D024802:Nurse's Role; D010353:Patient Education as Topic; D011565:Psoriasis / Q000145:classification / Q000188:drug therapy* / Q000276:immunology / Q000523:psychology; D011788:Quality of Life; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000627:therapeutic use*; D012074:Remission Induction / Q000379:methods; D012449:Safety; D012720:Severity of Illness Index; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D016896:Treatment Outcome
D011993:Recombinant Fusion Proteins; D000077944:Alefacept